Authors

Bruce E. Johnson, MD, Dana-Farber Cancer Institute

Bruce G. Raphael, MD

Latest:

Dr. Raphael on the Clinical Implications of the CLL14 Trial

Bruce G. Raphael, MD, discusses the utility of venetoclax and obinutuzumab in chronic lymphocytic leukemia.

Bruce L. Levine, PhD

Latest:

Dr. Levine on Programmed Anticancer Immunity With T-cell and NK-cell Therapies

Bruce L. Levine, PhD, discusses engineered anticancer immunity with T-cell and natural killer–cell therapies.

Bruce Roth, MD

Latest:

Dr. Roth on the Treatment of Cancers With Bevacizumab

Bruce Roth, MD, from the Siteman Cancer Center, Washington University School of Medicine, discusses the treatment of several cancers with bevacizumab.

Bruno Daniele, MD

Latest:

Dr. Daniele on Impact of Regorafenib in HCC

Bruno Daniele, MD, director, Department of Oncology and Medical Oncology, G. Rummo Hospital, Italy, discusses the potential impact of regorafenib (Stivarga) for the treatment of patients with hepatocellular carcinoma (HCC).

Bruno Sangro, MD, PhD

Latest:

Dr. Sangro on Updated Findings From the CheckMate-459 Trial in Advanced HCC

Bruno Sangro, MD, PhD, discusses the updated findings from the phase 3 CheckMate-459 trial, which evaluated the use of nivolumab and sorafenib in the treatment of patients with advanced hepatocellular carcinoma.

Bryan A. Mehlhaff, MD

Latest:

Dr. Mehlhaff on the Evolution of the Treatment Landscape in Prostate Cancer

Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses the ways in which the treatment landscape in prostate cancer has evolved in recent years.

Bryan A. Mehlhaff, MD, Oregon Urology Institute

Bryan Mehlhaff, MD

Latest:

Dr. Bryan Mehlhaff on PSA's Role in Prostate Cancer

Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses the controversy surrounding prostate-specific antigen (PSA) testing in prostate cancer.

Bryan R. Haugen, MD

Latest:

Dr. Haugen Describes the 82nd Annual ATA Meeting

Dr. Bryan Haugen, from University of Colorado School of Medicine, Describes the 82nd Annual Meeting of the American Thyroid Association.

Bryan Schneider, MD

Latest:

Dr Schneider on Targeted Treatment Options in MET Exon 14 Mutated–NSCLC

Bryan Schneider, MD, discusses agents available for use in the targeting of MET exon 14 mutations in non–small cell lung cancer.

By Alicia Bitterice, MSN, RN

Latest:

Managing Chemotherapy-Induced Peripheral Neuropathy

Chemotherapy-induced peripheral neuropathy is a common side effect in patients with cancer and nurses are essential to helping patients to manage this condition.

By Amy J. Hoffman, MSN, PhD, RN

Latest:

Making the Move to Exercise

Amy Hoffman, MSN, PhD, RN, from Michigan State University's College of Nursing, offers practical tips to help initiate a regular exercise strategy for cancer patients and survivors.

By Andre Goy, MD

Latest:

Does Lifestyle Matter to Prevent Cancer or Is It Just All “Bad Luck”?

We now have a better understanding of the sequence of events, particularly regarding the timing of these mutations, their impact, and some of the factors involved that might cause them.

By Andrew J. Bredemeyer, PhD

Latest:

Clinical Next-Generation Sequencing to Guide Cancer Treatment Decisions

In the past year, clinical laboratories have begun determining the tumor mutational status of multiple genes simultaneously using next-generation sequencing platforms.

By Andrew Smith

Latest:

Improving Practice Efficiency Through Emerging Technologies

The New Year offers little hope of breakthrough software improvements for medical practices, but experts say oncologists can still make 2015 a time of breakthrough productivity gains.

By Anita T. Shaffer

Latest:

Moving Beyond Targeted Therapy Stalwarts: Experts Weigh In on Four Tumor Types

OncologyLive asked experts in lymphoma, chronic myeloid leukemia, breast cancer, and nonâ€“small cell lung cancer to discuss the impact that the first targeted agents have had on these malignancies and the prospects for new therapeutic approaches.

By Ann Partridge, MD, MPH

Latest:

ï»¿Improving Cancer Survivorship: Embedding Tailored, Comprehensive Survivorship Care in the Breast Oncology Clinic

Ann Partridge, MD, MPH, from Dana-Farber Cancer Institute and Sandy Truong, a Harvard Medical School student, discuss the needs of cancer survivors and their efforts to optimize survivorship care.

By Arnold B. Etame, MD, PhD

Latest:

Neurosurgical Innovations Advance Safe Resection of Difficult Brain Tumors

Arnold B. Etame, MD, PhD, from the Moffitt Cancer Center, describes stereotactic neuronavigation, which may offer more surgical visualization capabilities for the neurosurgeon.

By Arta Monjazeb, MD

Latest:

Translating Combination Radiotherapy/Immunotherapy From Dogs to Humans With Advanced Melanoma or Sarcoma

Arta Monjazeb, MD, and Michael Kent, DVM, from the UC Davis Comprehensive Cancer Center, describe an early phase trial exploring the potential of translating successful treatment from dogs to humans with advanced melanoma or sarcoma.